Online inquiry

IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14338MR)

This product GTTS-WQ14338MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets EGFL7 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_016215.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51162
UniProt ID Q9UHF1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ14338MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9671MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ952MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-323
GTTS-WQ2153MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALD-518
GTTS-WQ4015MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BGB-A317
GTTS-WQ808MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ3899MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ13638MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ10790MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M777-16-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW